Table of Contents
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Product
1.1.2. Regional scope
1.1.3. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. GVR’s internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
1.9.1. Objective 1
1.9.2. Objective 2
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Product outlook
2.2.2. Regional outlook
2.3. Competitive Insights
Chapter 3. Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Market Dynamics
3.3.1. Market driver analysis
3.3.2. Market restraint analysis
3.4. Penetration & Growth Prospect Mapping
3.5. Global Epilepsy Drug Market Analysis Tools
3.5.1. Industry Analysis – Porter’s Five Forces
3.5.1.1. Supplier power
3.5.1.2. Buyer power
3.5.1.3. Substitution threat
3.5.1.4. Threat of new entrant
3.5.1.5. Competitive rivalry
3.5.2. PESTEL Analysis
3.5.2.1. Political landscape
3.5.2.2. Technological landscape
3.5.2.3. Economic landscape
Chapter 4. Epilepsy Drugs Market: Product Estimates & Trend Analysis
4.1. Epilepsy Drug Market: Key Takeaways
4.2. Epilepsy Drug Market: Product Movement & Market Share Analysis, 2022 & 2030
4.3. First Generation Anti-epileptics
4.3.1. First generation anti-epileptics market estimates and forecasts, 2018 to 2030 (USD Million)
4.4. Second Generation Anti-epileptics
4.4.1. Second generation anti-epileptics market estimates and forecasts, 2018 to 2030 (USD Million)
4.5. Third Generation Anti-epileptics
4.5.1. Third generation anti-epileptics market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 5. Epilepsy Drugs Market: Regional Estimates & Trend Analysis, by Drug
5.1. Regional Outlook
5.2. Epilepsy Drug Market by Region: Key Marketplace Takeaways
5.3. North America
5.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
5.3.2. U.S.
5.3.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
5.3.3. Canada
5.3.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
5.4. Europe
5.4.1. UK
5.4.1.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
5.4.2. Germany
5.4.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
5.4.3. France
5.4.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
5.4.4. Italy
5.4.4.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
5.4.5. Spain
5.4.5.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
5.4.6. Sweden
5.4.6.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
5.4.7. Norway
5.4.7.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
5.4.8. Denmark
5.4.8.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
5.5. Asia Pacific
5.5.1. Japan
5.5.1.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
5.5.2. China
5.5.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
5.5.3. India
5.5.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
5.5.4. Australia
5.5.4.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
5.5.5. Thailand
5.5.5.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
5.5.6. South Korea
5.5.6.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
5.6. Latin America
5.6.1. Brazil
5.6.1.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
5.6.2. Mexico
5.6.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
5.6.3. Argentina
5.6.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
5.7. MEA
5.7.1. Saudi Arabia
5.7.1.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
5.7.2. South Africa
5.7.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
5.7.3. UAE
5.7.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
5.7.4. Kuwait
5.7.4.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
Chapter 6. Competitive Landscape
6.1. Recent Developments & Impact Analysis, By Key Market Participants
6.2. Market Participant Categorization
6.2.1. UCB S.A., Belgium
6.2.1.1. Company Overview
6.2.1.2. Financial Performance
6.2.1.3. Product Benchmarking
6.2.1.4. Strategic Initiatives
6.2.2. Sanofi
6.2.2.1. Company Overview
6.2.2.2. Financial Performance
6.2.2.3. Product Benchmarking
6.2.2.4. Strategic Initiatives
6.2.3. Pfizer, Inc.
6.2.3.1. Company Overview
6.2.3.2. Financial Performance
6.2.3.3. Product Benchmarking
6.2.3.4. Strategic Initiatives
6.2.4. Otsuka America Pharmaceutical, Inc.
6.2.4.1. Company Overview
6.2.4.2. Financial Performance
6.2.4.3. Product Benchmarking
6.2.4.4. Strategic Initiatives
6.2.5. Eisai Co., Ltd.
6.2.5.1. Company Overview
6.2.5.2. Financial Performance
6.2.5.3. Product Benchmarking
6.2.5.4. Strategic Initiatives
6.2.6. Novartis AG
6.2.6.1. Company Overview
6.2.6.2. Financial Performance
6.2.6.3. Product Benchmarking
6.2.6.4. Strategic Initiatives
6.2.7. Abbott Laboratories, Inc.
6.2.7.1. Company Overview
6.2.7.2. Financial Performance
6.2.7.3. Product Benchmarking
6.2.7.4. Strategic Initiatives
6.2.8. Sanofi Aventis S.A.
6.2.8.1. Company Overview
6.2.8.2. Financial Performance
6.2.8.3. Product Benchmarking
6.2.8.4. Strategic Initiatives
6.2.9. GlaxoSmithKline plc
6.2.9.1. Company Overview
6.2.9.2. Financial Performance
6.2.9.3. Product Benchmarking
6.2.9.4. Strategic Initiatives
6.2.10. Sunovion Pharmaceuticals, Inc.
6.2.10.1. Company Overview
6.2.10.2. Financial Performance
6.2.10.3. Product Benchmarking
6.2.10.4. Strategic Initiatives
6.2.11. Jazz Pharmaceuticals plc
6.2.11.1. Company Overview
6.2.11.2. Financial Performance
6.2.11.3. Product Benchmarking
6.2.11.4. Strategic Initiatives
6.2.12. Neurelis, Inc.
6.2.12.1. Company Overview
6.2.12.2. Financial Performance
6.2.12.3. Product Benchmarking
6.2.12.4. Strategic Initiatives
|
